Leukemia Clinical Trials in Tennessee

Showing 341-360 of 814 trials

First in Human Study of M1069 in Advanced Solid Tumors

NCT05198349

The main purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early signs of efficacy of M1069 in participants with advanced solid malignancies.

Metastatic or Locally Advanced Unresectable Solid Tumors

EMD Serono Research & Development Institute, Inc.15 participantsStarted Mar 2022

Hackensack, New Jersey, United States • Nashville, Tennessee, United States • Toronto, Canada

COMPLETEDPHASE1/PHASE229 miles

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

NCT02614066

The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Kite, A Gilead Company125 participantsStarted Mar 2016

La Jolla, California, United States • Los Angeles, California, United States • Orange, California, United States +30 more locations

First in Human Study of M1069 in Advanced Solid Tumors

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Leukemia Trials in Other Cities

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Milademetan in Advanced/Metastatic Solid Tumors

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Other Conditions in Tennessee